Study Title
64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate Cancer.
Study Details
Description:
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticals (Clarity Clinical)clinicaltrials@claritypharmaceuticals.com
+61 0 2 9209 4037
Government Study Link:
NCT05407311 - Click here to see study onClinicalTrials.gov
Inclusion
- • Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy
- • Negative or equivocal findings for PC
- • Adequate liver function
- • Estimated Glomerular Filtration Rate of 30 mL/min or higher.
- • Suspected recurrence of prostate cancer (PC) based on rising Prostate specific antigen (PSA) after definitive therapy
Exclusion
- •Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedure
- • Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States